Globally, patients living with sickle cell disease are now surviving to reproductive age, with life expectancy approaching 50 years in most countries. Thus, reproductive options are now essential for patients living with the condition. However, it can be associated with maternal, delivery, and fetal complications. Outcomes may vary depending on the level of expertise and resources. In this piece we provide an optional guideline for managing sickle cell disease in pregnancy. The therapeutic option of serial exchange prophylactic transfusion has been offered in the context of a clinical trial (TAPS2).

Original languageEnglish
Pages (from-to)408-413
Number of pages6
JournalHematology. American Society of Hematology. Education Program
Issue number1
Publication statusPublished - 9 Dec 2022


Dive into the research topics of 'Evidence-based management of pregnant women with sickle cell disease in high-income countries'. Together they form a unique fingerprint.

Cite this